“Pancreatic Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Cancer Market.
The Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Pancreatic Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Pancreatic Cancer treatment therapies with a considerable amount of success over the years.
Pancreatic Cancer companies working in the treatment market are Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others, are developing therapies for the Pancreatic Cancer treatment
Emerging Pancreatic Cancer therapies in the different phases of clinical trials are- IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others are expected to have a significant impact on the Pancreatic Cancer market in the coming years.
In September 2024, Trishula Therapeutics, a US-based biotechnology company, has announced positive findings from its Phase I clinical trial of TTX-030, an anti-CD39 antibody developed for the treatment of first-line metastatic pancreatic cancer. The trial evaluated TTX-030 in combination with gemcitabine and nab-paclitaxel, both with and without the investigational anti-PD-1 antibody budigalimab, in patients with pancreatic adenocarcinoma. The results revealed an objective response rate (ORR) of 30%, a median progression-free survival of 7.5 months, and a median overall survival of 19.1 months in the efficacy-evaluable group.
In May 2024, Verastem Oncology has announced promising early results from its ongoing Phase I/II trial evaluating the kinase inhibitor avutometinib for pancreatic cancer treatment. The US-based biopharmaceutical company shared these interim safety and efficacy findings ahead of its presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, set for June 1, 2024. The trial, known as RAMP 205, is a single-arm study assessing the combination of avutometinib and defactinib with standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
In March 2024, Catalan biopharmaceutical company AbilityPharma has obtained a €7m ($7.65m) investment to advance its Phase IIb clinical trial of ABTL0812, an autophagy inducer aimed at treating metastatic pancreatic cancer. This funding round saw participation from a European-Canadian life sciences syndicate, including CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent, and CDTI Innvierte.
Pancreatic Cancer Overview
Pancreatic cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.
Get a Free Sample PDF Report to know more about Pancreatic Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight
Emerging Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:
IMC-R117C: Immunocore
CT7001: Carrick Therapeutics
DK210: DEKA Biosciences
CMG901: Keymed Biosciences
AB011: CARsgen Therapeutics
Rintatolimod: AIM ImmunoTech Inc.
RXC004: Redx Pharma Plc
RAIN-32: Rain Oncology
Pamrevlumab: FibroGen
NIS793: Novartis AG
Pembrolizumab: Merck & Co
Lynparza: AstraZeneca
Pancreatic Cancer Route of Administration
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Pancreatic Cancer Molecule Type
Pancreatic Cancer Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Pancreatic Cancer Pipeline Therapeutics Assessment
Pancreatic Cancer Assessment by Product Type
Pancreatic Cancer By Stage and Product Type
Pancreatic Cancer Assessment by Route of Administration
Pancreatic Cancer By Stage and Route of Administration
Pancreatic Cancer Assessment by Molecule Type
Pancreatic Cancer by Stage and Molecule Type
DelveInsight’s Pancreatic Cancer Report covers around 300+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Pancreatic Cancer product details are provided in the report. Download the Pancreatic Cancer pipeline report to learn more about the emerging Pancreatic Cancer therapies
Some of the key companies in the Pancreatic Cancer Therapeutics Market include:
Key companies developing therapies for Pancreatic Cancer are – AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.
Pancreatic Cancer Pipeline Analysis:
The Pancreatic Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer Treatment.
Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Pancreatic Cancer drugs and therapies
Pancreatic Cancer Pipeline Market Drivers
Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Pancreatic Cancer Market.
Pancreatic Cancer Pipeline Market Barriers
However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in pancreatic cancer and other factors are creating obstacles in the Pancreatic Cancer Market growth.
Scope of Pancreatic Cancer Pipeline Drug Insight
Coverage: Global
Key Pancreatic Cancer Companies: Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others
Key Pancreatic Cancer Therapies: IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others
Pancreatic Cancer Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies
Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and Pancreatic Cancer market barriers
Request for Sample PDF Report for Pancreatic Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Pancreatic Cancer Report Introduction
2. Pancreatic Cancer Executive Summary
3. Pancreatic Cancer Overview
4. Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Cancer Pipeline Therapeutics
6. Pancreatic Cancer Late Stage Products (Phase II/III)
7. Pancreatic Cancer Mid Stage Products (Phase II)
8. Pancreatic Cancer Early Stage Products (Phase I)
9. Pancreatic Cancer Preclinical Stage Products
10. Pancreatic Cancer Therapeutics Assessment
11. Pancreatic Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pancreatic Cancer Key Companies
14. Pancreatic Cancer Key Products
15. Pancreatic Cancer Unmet Needs
16 . Pancreatic Cancer Market Drivers and Barriers
17. Pancreatic Cancer Future Perspectives and Conclusion
18. Pancreatic Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
